• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于预后列线图的生存风险分层,以确定可能从术后辅助治疗中获益的食管鳞癌患者。

Survival risk stratification based on prognosis nomogram to identify patients with esophageal squamous cell carcinoma who may benefit from postoperative adjuvant therapy.

机构信息

Department of Radiation Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, 200092, China.

Department of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.

出版信息

BMC Cancer. 2024 Oct 29;24(1):1330. doi: 10.1186/s12885-024-13085-w.

DOI:10.1186/s12885-024-13085-w
PMID:39472872
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11520824/
Abstract

OBJECTIVE

The purpose of the study is to develop a prognosis nomogram for esophageal squamous cell carcinoma (ESCC) patients with radical resection and to identify patients who may benefit from postoperative adjuvant radiotherapy/chemoradiotherapy through survival risk stratification.

METHODS

We retrospectively enrolled patients who underwent esophagectomy in the First Affiliated Hospital of Nanjing Medical University from July 2015 to June 2017. Patients with stage I-III esophageal squamous cell carcinoma who received radical R0 resection with or without postoperative adjuvant radiotherapy/chemoradiotherapy were included. Further, patients were randomly allocated into two groups (training and validation cohorts) with a distribution ratio of 7:3. The prognosis nomogram was constructed based on independent factors determined by univariate and multivariate Cox analyses. The area under the receiver operating characteristic curve (AUC) and calibration curve were adopted to evaluate the discriminative ability and reliability of the nomogram. The accuracy and clinical practicability were respectively assessed by C-index values and decision curve analysis (DCA), and further contrasted the nomogram model and the eighth edition of the American Joint Committee on Cancer (AJCC) TNM staging system. In addition, survival risk stratification was further performed according to the nomogram, and the effect of postoperative adjuvant therapy on each risk group was appraised by the Kaplan-Meier survival analysis.

RESULTS

A total of 399 patients with esophageal squamous cell carcinoma were recruited in this study, including the training cohort (n = 280) and the validation cohort (n = 119). The nomogram-related AUC values ​​for 1, 3, and 5-year OS were 0.900, 0.795, and 0.802, respectively, and 0.800, 0.865, 0.829 in the validation cohort, respectively. The slope of the calibration curve for both cohorts was close to 1, indicating good consistency. The C-index value of the nomogram was 0.769, which was higher than that of the AJCC 8th TNM staging system by 0.061 (p < 0.001). Based on the prognosis nomogram, patients were stratified into three risk groups (low, medium, and high), and there were obvious differences in prognosis among the groups (p < 0.001). Furthermore, postoperative adjuvant therapy has been shown to enhance the 5-year survival rate by over 15% among patients classified as medium- and high-risk.

CONCLUSION

The constructed nomogram as developed resulted in accurate and effective prediction performance in survival outcomes for patients with stage I-III esophageal squamous cell carcinoma who underwent radical R0 resection, which is superior to the AJCC 8th TNM staging system. The survival risk stratification had potential clinical application to guide further personalized adjuvant therapy.

摘要

目的

本研究旨在为接受根治性切除术的食管鳞癌(ESCC)患者制定预后列线图,并通过生存风险分层确定可能从术后辅助放化疗中获益的患者。

方法

我们回顾性纳入 2015 年 7 月至 2017 年 6 月在南京医科大学第一附属医院接受食管切除术的患者。纳入接受根治性 R0 切除术且术后接受或未接受辅助放化疗的 I-III 期食管鳞癌患者。进一步将患者随机分为两组(训练队列和验证队列),分布比例为 7:3。基于单因素和多因素 Cox 分析确定的独立因素构建预后列线图。采用接受者操作特征曲线(ROC)下面积(AUC)和校准曲线评估列线图的判别能力和可靠性。通过 C 指数值和决策曲线分析(DCA)评估准确性和临床实用性,并进一步比较列线图模型和第八版美国癌症联合委员会(AJCC)TNM 分期系统。此外,根据列线图进行生存风险分层,并通过 Kaplan-Meier 生存分析评估术后辅助治疗对每个风险组的影响。

结果

本研究共纳入 399 例食管鳞癌患者,包括训练队列(n=280)和验证队列(n=119)。1、3、5 年 OS 的列线图相关 AUC 值分别为 0.900、0.795 和 0.802,验证队列分别为 0.800、0.865 和 0.829。两个队列的校准曲线斜率接近 1,提示一致性良好。列线图的 C 指数值为 0.769,高于第八版 AJCC TNM 分期系统的 0.061(p<0.001)。基于预后列线图,患者被分为低、中、高三个风险组,组间预后差异明显(p<0.001)。此外,中高危患者接受术后辅助治疗可使 5 年生存率提高 15%以上。

结论

本研究构建的列线图可准确有效地预测接受根治性 R0 切除术的 I-III 期食管鳞癌患者的生存结局,优于第八版 AJCC TNM 分期系统。生存风险分层具有潜在的临床应用价值,可指导进一步的个体化辅助治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20e1/11520824/68c92165c607/12885_2024_13085_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20e1/11520824/af14f8ebf281/12885_2024_13085_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20e1/11520824/989200f36883/12885_2024_13085_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20e1/11520824/2d510cd58ad9/12885_2024_13085_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20e1/11520824/0036fa55cc37/12885_2024_13085_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20e1/11520824/8c4a47e70a39/12885_2024_13085_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20e1/11520824/9b6ad2642097/12885_2024_13085_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20e1/11520824/aa27daec342c/12885_2024_13085_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20e1/11520824/68c92165c607/12885_2024_13085_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20e1/11520824/af14f8ebf281/12885_2024_13085_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20e1/11520824/989200f36883/12885_2024_13085_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20e1/11520824/2d510cd58ad9/12885_2024_13085_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20e1/11520824/0036fa55cc37/12885_2024_13085_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20e1/11520824/8c4a47e70a39/12885_2024_13085_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20e1/11520824/9b6ad2642097/12885_2024_13085_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20e1/11520824/aa27daec342c/12885_2024_13085_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20e1/11520824/68c92165c607/12885_2024_13085_Fig8_HTML.jpg

相似文献

1
Survival risk stratification based on prognosis nomogram to identify patients with esophageal squamous cell carcinoma who may benefit from postoperative adjuvant therapy.基于预后列线图的生存风险分层,以确定可能从术后辅助治疗中获益的食管鳞癌患者。
BMC Cancer. 2024 Oct 29;24(1):1330. doi: 10.1186/s12885-024-13085-w.
2
Nomogram to Predict Overall Survival for Thoracic Esophageal Squamous Cell Carcinoma Patients After Radical Esophagectomy.列线图预测根治性食管切除术后胸段食管鳞癌患者的总生存。
Ann Surg Oncol. 2019 Sep;26(9):2890-2898. doi: 10.1245/s10434-019-07393-w. Epub 2019 Jun 10.
3
Prognostic nomogram for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy followed by adjuvant chemotherapy.食管鳞状细胞癌患者接受食管切除术后辅助化疗,针对此前未接受过治疗患者的预后列线图。
Jpn J Clin Oncol. 2016 Apr;46(4):336-43. doi: 10.1093/jjco/hyv206. Epub 2016 Jan 26.
4
Predictive potential of preoperative Naples prognostic score-based nomogram model for the prognosis in surgical resected thoracic esophageal squamous cell carcinoma patients: A retrospective cohort study.基于术前那不勒斯预后评分的列线图模型对手术切除的胸段食管鳞状细胞癌患者预后的预测潜力:一项回顾性队列研究。
Medicine (Baltimore). 2024 May 3;103(18):e38038. doi: 10.1097/MD.0000000000038038.
5
Nomogram based on pretreatment hepatic and renal function indicators for survival prediction of locally advanced esophageal squamous cell carcinoma with treatment of neoadjuvant chemoradiotherapy plus surgery.基于治疗前肝肾功能指标的列线图预测新辅助放化疗加手术治疗局部晚期食管鳞癌的生存。
Updates Surg. 2024 Aug;76(4):1377-1388. doi: 10.1007/s13304-023-01693-3. Epub 2023 Nov 13.
6
Development and validation of a new clinical staging system to predict survival for esophageal squamous cell carcinoma patients: Application of the nomogram.开发和验证一种新的临床分期系统,以预测食管鳞癌患者的生存情况:列线图的应用。
Eur J Surg Oncol. 2021 Jun;47(6):1473-1480. doi: 10.1016/j.ejso.2020.12.004. Epub 2021 Jan 19.
7
Prognostic nomogram integrated systemic inflammation score for patients with esophageal squamous cell carcinoma undergoing radical esophagectomy.接受根治性食管切除术的食管鳞状细胞癌患者的预后列线图综合全身炎症评分
Sci Rep. 2015 Dec 22;5:18811. doi: 10.1038/srep18811.
8
Prognostic factors for patients with pathologic T1-T2N+ esophageal squamous cell carcinoma: A retrospective study with external validation.T1-T2N+ 期食管鳞癌患者的预后因素:一项回顾性研究及外部验证。
Surgery. 2024 Sep;176(3):730-738. doi: 10.1016/j.surg.2024.05.026. Epub 2024 Jun 19.
9
The value of complete blood count for the prognosis analysis of preoperative esophageal squamous cell carcinoma.全血细胞计数对术前食管鳞癌预后分析的价值。
BMC Cancer. 2021 Sep 30;21(1):1072. doi: 10.1186/s12885-021-08789-2.
10
Development of a Survival Nomogram for Esophageal Squamous Cell Carcinoma Patients: a Population-Based Analysis.基于人群的分析:食管鳞癌患者生存列线图的建立。
J Gastrointest Cancer. 2024 Mar;55(1):391-401. doi: 10.1007/s12029-023-00975-8. Epub 2023 Oct 7.

本文引用的文献

1
Lymphovascular space invasion in endometrial carcinoma: A prognostic factor independent from molecular signature.子宫内膜癌中的淋巴管间隙浸润:一个独立于分子特征的预后因素。
Gynecol Oncol. 2022 Apr;165(1):192-197. doi: 10.1016/j.ygyno.2022.01.013. Epub 2022 Jan 23.
2
Recurrence risk stratification based on a competing-risks nomogram to identify patients with esophageal cancer who may benefit from postoperative radiotherapy.基于竞争风险列线图的复发风险分层,以识别可能从术后放疗中获益的食管癌患者。
Ther Adv Med Oncol. 2021 Dec 20;13:17588359211061948. doi: 10.1177/17588359211061948. eCollection 2021.
3
Prognosis of Patients with Esophageal Carcinoma After Routine Thoracic Duct Resection: A Propensity-matched Analysis of 12,237 Patients Based on the Comprehensive Registry of Esophageal Cancer in Japan.
常规胸导管切除术后食管癌患者的预后:基于日本食管癌综合登记数据库的 12237 例患者倾向性匹配分析。
Ann Surg. 2023 May 1;277(5):e1018-e1025. doi: 10.1097/SLA.0000000000005340. Epub 2023 Apr 6.
4
Development of immune gene pair-based signature predictive of prognosis and immunotherapy in esophageal cancer.基于免疫基因对的特征在食管癌预后及免疫治疗预测中的研究进展
Ann Transl Med. 2021 Oct;9(20):1591. doi: 10.21037/atm-21-5217.
5
Predicting response to immunotherapy plus chemotherapy in patients with esophageal squamous cell carcinoma using non-invasive Radiomic biomarkers.利用无创放射组学生物标志物预测食管鳞癌患者免疫联合化疗的反应。
BMC Cancer. 2021 Oct 30;21(1):1167. doi: 10.1186/s12885-021-08899-x.
6
Postoperative Adjuvant Therapy Versus Surgery Alone for Stage IIB-III Esophageal Squamous Cell Carcinoma: A Phase III Randomized Controlled Trial.根治性手术与术后辅助放化疗治疗 IIB-III 期食管鳞癌的随机对照 III 期临床研究
Oncologist. 2021 Dec;26(12):e2151-e2160. doi: 10.1002/onco.13914. Epub 2021 Aug 19.
7
New Trends in Esophageal Cancer Management.食管癌治疗的新趋势
Cancers (Basel). 2021 Jun 17;13(12):3030. doi: 10.3390/cancers13123030.
8
A novel nomogram with preferable capability in predicting the overall survival of patients after radical esophageal cancer resection based on accessible clinical indicators: A comparison with AJCC staging.一种基于可获得的临床指标,具有更好预测根治性食管癌切除术后患者总生存能力的新型列线图:与 AJCC 分期的比较。
Cancer Med. 2021 Jul;10(13):4228-4239. doi: 10.1002/cam4.3878. Epub 2021 Jun 15.
9
Is Adjuvant Therapy a Better Option for Esophageal Squamous Cell Carcinoma Patients Treated With Esophagectomy? A Prognosis Prediction Model Based on Multicenter Real-World Data.辅助治疗对接受食管切除术的食管鳞状细胞癌患者来说是更好的选择吗?基于多中心真实世界数据的预后预测模型
Ann Surg. 2023 Jan 1;277(1):e61-e69. doi: 10.1097/SLA.0000000000004958. Epub 2021 Jun 2.
10
Esophageal Cancer in Elderly Patients, Current Treatment Options and Outcomes; A Systematic Review and Pooled Analysis.老年患者的食管癌:当前治疗选择与结果;系统评价与汇总分析
Cancers (Basel). 2021 Apr 27;13(9):2104. doi: 10.3390/cancers13092104.